8th Annual USC Multidisciplinary Breast Cancer Symposium

 

8th Annual USC Multidisciplinary Breast Cancer Symposium
G

HR+HER2- High-Risk eBC: Surveying Efficacy Data of CDK4/6i in the Adjuvant Setting

By 8th Annual USC Multidisciplinary Breast Cancer Symposium FEATURING George Sledge
By 8th Annual USC Multidisciplinary Breast Cancer Symposium FEATURING George Sledge
186 views
February 22, 2021
This video was completed prior to Abemaciclib receiving FDA approval on 10/12/21
0 Comments
Login to view comments. Click here to Login
Videos
05:35
8th Annual USC Multidisciplinary Breast Cancer Symposium

HR+HER2- High-Risk eBC: Surveying Efficacy Data of CDK4/6i in the Ad…

Feat. G. Sledge
09:19
8th Annual USC Multidisciplinary Breast Cancer Symposium

HR+/HER2- MBC: Outcomes of 1/2L CDK4/6 Inhibition

Feat. G. Sledge
09:50
8th Annual USC Multidisciplinary Breast Cancer Symposium

ER+ Early Stage BC: Which Patients Should Avoid Chemotherapy? Does C…

Feat. G. Sledge
06:22
8th Annual USC Multidisciplinary Breast Cancer Symposium

PI3K/AKT/mTOR Inhibition in Advanced BC: Is There Any Benefit With A…

Feat. G. Sledge
30:59
8th Annual USC Multidisciplinary Breast Cancer Symposium

Genetic Risk in BC: BRCA1/2 Mutations, Genetic Testing, Preventive B…

Feat. B. Arun
35:08
8th Annual USC Multidisciplinary Breast Cancer Symposium

Oncoplastic Surgery and BC: What Is Extreme Oncoplasty? When Can We …

Feat. M. Silverstein
28:38
8th Annual USC Multidisciplinary Breast Cancer Symposium

Diagnostic MRI for Newly Diagnosed BC: Factors of Occult Lesions Det…

Feat. S. Sener
39:07
8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Challenges in HER2+ BC Testing: IHC Guidelines, Biomarker Testi…

Feat. M. Press
18:27
8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Updates on HER2+ MBC: What Does the New Data on T-DXd Suggest? …

Feat. W. Gradishar
11:34
8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Updates on HER2+ MBC: Tucatinib Combo and HRQoL in Brain Mets, …

Feat. W. Gradishar
19:06
8th Annual USC Multidisciplinary Breast Cancer Symposium

USC Update on 1L Chemo Combination for Advanced TNBC: Does the Addit…

Feat. S. Hurvitz
06:31
8th Annual USC Multidisciplinary Breast Cancer Symposium

Innovations in Management of mTNBC: PARP Inhibitors

Feat. S. Hurvitz
13:11
8th Annual USC Multidisciplinary Breast Cancer Symposium

Clinical Trial Data on ADCs in TNBC: Sacituzumab Govitecan Efficacy …

Feat. S. Hurvitz